Tag: Cagent Vascular
PRELUDE-BTK subanalysis “suggests advantage” for serration angioplasty
Cagent Vascular has announced the results of a comparative subanalysis of the PRELUDE-below-the-knee (BTK) study versus plain balloon angioplasty.
The study was led by Marianne...
Sectoral Asset Management makes US$9 million investment into Cagent Vascular
Cagent Vascular recently announced the investment of US$9 million by Sectoral Asset Management. Along with the investment, Marc-Andre Marcotte has joined the board of...
LINC 2021: PRELUDE-BTK results confirm Serranator device novel mechanism of action
Cagent Vascular announced the results of its PRELUDE-BTK study at LINC 2021 (25–29 January, online). The PRELUDE-BTK study was a prospective, single-arm, multicentre feasibility...
Cagent Vascular raises US$11.87M funding
Cagent Vascular has announced the completion of US$11.87 million in Series B funding. The round was led by two strategic investors including one that...
